The main risk of thrombolytic drugs is that they may cause bleeding in patients, so patients should be monitored for vital signs during the use of thrombolytic drugs and within 24 hours of administration. The use of thrombolytic drugs is a very effective clinical treatment for cerebral infarction disease. In neurology, patients can be treated with intravenous thrombolytic drugs if they have indications for thrombolysis within 6 hours of onset and if contraindications to thrombolysis are excluded. The time window for effective resuscitation of the ischemic semidark zone around the necrotic brain tissue is usually considered to be within 4.5 hours of onset with rt-PA and within 6 hours of onset with urokinase. Contraindications to intravenous thrombolysis must be noted if the patient has a previous history of intracranial hemorrhage or the presence of intracranial arteriovenous malformations, aneurysms, brain tumors, and a history of severe cranial trauma. In these cases, thrombolytic drugs are not suitable for treatment and the benefits and risks to the patient must be carefully weighed.